A phase II trial of sorafenib (S) and dacarbazine (D) in leiomyosarcoma (LMS), synovial sarcoma (SS), and malignant peripheral nerve sheath tumor (MPNST).
D. R. D'Adamo
Honoraria - Bayer
Research Funding - Bayer
M. L. Keohan
No relevant relationships to disclose
R. D. Carvajal
No relevant relationships to disclose
M. L. Hensley
No relevant relationships to disclose
C. Hirst
No relevant relationships to disclose
L. Qin
No relevant relationships to disclose
C. Antonescu
No relevant relationships to disclose
R. A. Lefkowitz
No relevant relationships to disclose
G. K. Schwartz
No relevant relationships to disclose
R. G. Maki
Honoraria - Bayer